Skip to main content
Sanofi logo

Sanofi — Investor Relations & Filings

Ticker · SAN ISIN · FR0000120578 LEI · 549300E9PC51EN656011 PA Manufacturing
Open in API
Filings indexed 4,414 across all filing types
Latest filing 2024-11-20 Declaration of Voting R…
Country FR France
Listing PA SAN

About Sanofi

https://www.sanofi.com/en/directory/

Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
Sanofi: Information concerning the total number of voting rights and shares - October 2024
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document explicitly states it concerns the 'total number of voting rights and shares' pursuant to French commercial code and AMF regulations. It provides a table detailing the total number of issued shares and the number of voting rights as of a specific date (October 31, 2024). This type of mandatory disclosure regarding the capital structure and voting power aligns most closely with announcements related to share capital changes or regulatory reporting on share ownership, but none of the specific codes perfectly match a 'Total Voting Rights' disclosure. Reviewing the definitions: - SHA (Share Issue/Capital Change): This is a strong candidate as voting rights are intrinsically linked to the capital structure. - MRQ (Major Shareholding Notification): This usually relates to crossing ownership thresholds, not the total count. - DVA (Declaration of Voting Results & Voting Rights Announcements): This is typically for the *results* of a vote, not the total potential voting rights. Given the content is a formal, periodic declaration of the total number of shares and voting rights, it is a fundamental disclosure about the company's share capital structure. Therefore, 'Share Issue/Capital Change' (SHA) is the most appropriate fit among the provided options, as it deals directly with the composition of the share base. However, since this is a specific regulatory filing about the total number of shares and voting rights (often required monthly in Europe), and it doesn't announce a new issue or buyback, it could also be considered a general regulatory filing (RNS). But because it is a specific disclosure about the *number* of shares/rights, SHA is preferred over the general RNS fallback. The document is short and contains the required data directly, so it is not an RPA.
2024-11-20 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It includes references to press releases attached as exhibits, which are typical for 6-K filings that provide updates or announcements but do not contain full financial statements or detailed reports. The document length is short (1509 characters), and it primarily announces press releases rather than providing comprehensive financial data or management discussion. Therefore, it does not qualify as an Annual Report (10-K), Interim Report (IR), or Earnings Release (ER). It is a regulatory filing providing updates and disclosures as required by the SEC for foreign issuers. Hence, the appropriate classification is Regulatory Filings (RNS).
2024-11-18 English
Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria
Regulatory Filings Classification · 95% confidence The document is explicitly titled "Press Release" and details a specific corporate event: the FDA's acceptance of a supplemental Biologics License Application (sBLA) for Dupixent for Chronic Spontaneous Urticaria (CSU), including key data points and target decision dates. This format—a formal announcement of a regulatory milestone or key business update, often released before a full quarterly or annual report—aligns best with an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it focuses on a specific, time-sensitive regulatory/clinical update rather than general financial performance (ER) or a broad regulatory filing fallback (RNS), and given the context of drug development news, it functions as a major corporate announcement. However, among the provided codes, 'ER' (Earnings Release) is often used broadly for major periodic financial/operational updates, but this is purely clinical/regulatory news. Since it is a press release announcing a specific regulatory action (FDA acceptance/target date), and it is not a transcript (CT), a formal report (10-K, IR), or a proxy statement (DEF 14A), the most appropriate classification for a significant, non-financial, non-meeting-related corporate announcement that doesn't fit other specific categories is the general Regulatory Filings (RNS) or potentially an Earnings Release (ER) if the database lumps all major announcements there. Given the content is a press release about FDA action, it is a standard form of regulatory communication. I will classify it as RNS as it is a general regulatory announcement that doesn't fit the more specific categories like DIV, CAP, or MANG.
2024-11-15 English
Communiqué de presse : La FDA a accepté l’examen de la sBLA pour le Dupixent dans le traitement de l’urticaire chronique spontanée
Regulatory Filings Classification · 100% confidence The document is titled "Communiqué de presse" (Press Release) and announces that the FDA has accepted the review of a Supplemental Biologics License Application (sBLA) for Dupixent for Chronic Spontaneous Urticaria (CSU). It details clinical trial data, regulatory timelines (FDA action date expected April 18, 2025), and provides standard boilerplate information about the drug, the companies (Sanofi and Regeneron), and includes forward-looking statements typical of corporate news releases. This is not a formal regulatory filing like a 10-K or an IR. It is an announcement regarding regulatory progress and clinical data, which fits best under the category of an Earnings Release (ER) if it were quarterly results, but since it is a specific corporate/product development announcement, it is most closely aligned with a general corporate announcement or a specific type of release. Given the options, this type of announcement, which releases key business/regulatory news outside of scheduled earnings, often falls under the general 'Regulatory Filings' (RNS) if no better fit exists, or sometimes an 'Earnings Release' (ER) if it contains key performance indicators, though this is focused on regulatory acceptance. However, looking closely at the definitions: - ER (Earnings Release): Initial announcement of *quarterly/periodical financial results* (key highlights only). This document focuses on regulatory acceptance and clinical data, not financial results. - RNS (Regulatory Filings): General regulatory announcements and fallback category. Since this is a press release announcing a significant regulatory milestone (FDA acceptance of sBLA), it functions as a key corporate/regulatory update. In many databases, such specific, non-financial, non-meeting-related announcements default to a general regulatory/news category. 'RNS' (Regulatory Filings) serves as the best general category for significant, non-standard corporate news releases that aren't explicitly covered elsewhere (like M&A, Dividends, or Management changes). It is a formal communication to the market about a regulatory event. I will classify this as RNS (Regulatory Filings) as it is a press release detailing a regulatory submission acceptance, which is a form of regulatory communication that doesn't fit the other specific categories like ER (financial results) or LTR (legal proceedings).
2024-11-15 French
Communiqué de presse : Sarclisa : approbation recommandée par le CHMP dans l’UE pour le traitement du myélome multiple nouvellement diagnostiqué non éligible à une greffe
Regulatory Filings Classification · 100% confidence The document is titled 'Communiqué de presse' (Press Release) and announces a positive opinion from the CHMP (Committee for Medicinal Products for Human Use) of the EMA regarding the marketing authorization application for the drug Sarclisa. It details clinical trial results (IMROZ study) and regulatory milestones (FDA approval in September 2024, CHMP recommendation in November 2024). This type of announcement, focusing on a specific regulatory or clinical development update, is characteristic of an Earnings Release (ER) if it were quarterly results, but since it is a specific, non-periodic announcement about a drug approval/recommendation, it fits best under the general category for regulatory announcements or press releases that don't fit elsewhere. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a general press release detailing regulatory progress, although it is not a formal SEC filing like a 10-K or 8-K. However, since it is a press release announcing a major regulatory event (CHMP opinion), and it is not a full financial report (10-K, IR) or a transcript (CT), RNS serves as the best fit for a general corporate announcement of this nature that isn't covered by other specific codes like DIV or MANG. It is not a Report Publication Announcement (RPA) because it is the primary news, not an announcement *about* the publication of a separate, attached report.
2024-11-14 French
Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma
Regulatory Filings Classification · 100% confidence The document is explicitly titled "Press Release" and details a positive opinion from the CHMP (Committee for Medicinal Products for Human Use) regarding the EU approval recommendation for the drug Sarclisa. It includes key financial/operational highlights, quotes from management, references to clinical trial data (IMROZ phase 3 study), and standard forward-looking statements typical of corporate announcements regarding regulatory milestones. This structure strongly indicates an Earnings Release (ER) or a general corporate announcement. Since it focuses on a specific regulatory/clinical milestone rather than comprehensive financial results (like a 10-K or IR), and it is presented as a 'Press Release' announcing a key development, 'ER' (Earnings Release) is the closest fit among the options for a major, time-sensitive corporate update, although 'RNS' (Regulatory Filings) is also plausible for non-earnings regulatory news. Given the nature of drug approval news, which often drives market sentiment and is released via press release, ER is often used for significant operational news outside of standard quarterly reporting, or it could be classified as RNS if ER is strictly reserved for financial results. However, in many contexts, major press releases announcing significant operational achievements (like regulatory approvals) are grouped with ERs or treated as a high-priority announcement. Since it is a formal press release announcing a major regulatory event, and not a transcript (CT), a full annual report (10-K), or a specific dividend notice (DIV), it fits best as a general corporate announcement. Given the options, 'ER' covers major press releases announcing significant operational news, or 'RNS' as a fallback. I will select 'ER' as it is a major, time-sensitive announcement intended for broad market dissemination, similar in function to an earnings release in terms of market impact, but 'RNS' is the safest fallback for non-financial regulatory news. Given the context of a major drug approval announcement, which is a key operational event, I will lean towards 'ER' as the primary classification for a major press release, but acknowledge the ambiguity. Re-evaluating the definitions: ER is for 'Initial announcement of quarterly/periodical financial results (key highlights only)'. This is not financial results. Therefore, the best fit is 'RNS' (General regulatory announcements and fallback category for miscellaneous filings that do not neatly fit into other specific categories).
2024-11-14 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.